Bilaal.Raja
Company record

ACAD  ACADIA PHARMACEUTICALS INC

Trailing twelve months to 2026-06-30, as filed 2026-08-05 and not restated since.
Healthcare

Scale

Market cap
$5.1bn
Revenue TTM
$1.1bn
Net income TTM
$380m
Free cash flow
$146m
Composite score
55.8
Sector rank
#1065

Valuation

P / E
13.4
EV / EBITDA
42.2
EV / sales
3.6
FCF yield
2.85%
Yield vs 10-yr
2.72pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
33.4%
EBITDA margin
8.6%
ROE
29.1%
ROIC
24.7%
Revenue growth
11.8%

Insider activity, last 90 days

Net open-market
$-1.32m
Buyers
0
Sellers
3

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Net product sales from these two commercial products totaled $576.0 million for the six months ended June 30, 2026, compared with $508.9 million for the six months ended June 30, 2025. License fees and royalties also include royalties of tiered, escalating, double-digit percentages due to Neuren based upon net sales of DAYBUE products. Comparison of the Three Months Ended June 30, 2026 and 2025 Product Sales, Net Net product sales, comprised of NUPLAZID and DAYBUE products, were $308.0 million and $264.6 million for the three months ended June 30, 2026 and 2025, respectively. …ACADIA PHARMACEUTICALS INC, 10-Q, period ended 2026-06-30, filed 2026-08-05

Read the full passage →